Oncology

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

The review and re-appraisal of the use of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma has resulted in a change in the guidance.
Read more

 http://www.nice.org.uk/guidance/index.jsp?action=byID&o=1192...

National Institute for Health and Clinical Excellence